In sorafenib-resistant HLE cells, ATF4 mediated the upregulation of SLC7A11 expression to elevate glutathione (GSH) levels, reduce ROS levels and inhibit ferroptosis, making HCC cells survive in the presence of sorafenib. Here, ATF4 is linked to hepatocellular carcinoma.